Consequently, inhibition of the PCA pathway confers increased susceptibility to antifungal drugs, thus revealing a therapeutic strategy for potentiation of frontline antifungal drugs to prevent fungal infections. This evidence concerns the gene FLVCR1 and fungal infectious disease.